Bhavith Aruni Babu
Interventional Cardiology · Pueblo, CONPI 1841587938
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,500 of the $49,523 with a category attached, or 69.7%. Abiomed accounts for 78.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $14,921 and has fallen 90.5% since, to $1,414 in 2025.
Across 281 payments — averaging $176.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$39K
- Edwards Lifesciences$4K
- Medtronic$3K
- Abbott$1K
- Boston Scientific$614
- Shockwave Medical, Inc$379
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$34,50070%
- Travel & lodging$5,43111%
- Food & beverage$9,59219%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 67 | $38,884 |
| Edwards Lifesciences | 50 | $4,456 |
| Medtronic(2 entities) | 45 | $2,668 |
| Abbott | 45 | $1,328 |
| Boston Scientific | 15 | $614 |
| Shockwave Medical, Inc | 10 | $379 |
| E.r. Squibb & Sons, L.L.C. | 11 | $181 |
| Penumbra, Inc. | 1 | $150 |
| Verge Medical, Inc. | 1 | $144 |
| Amgen | 7 | $113 |
| Teleflex LLC | 2 | $111 |
| Cardiovascular Systems Inc. | 3 | $110 |
| Novartis | 5 | $98 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $89 |
| Cardiva Medical, Inc. | 3 | $51 |
| Merck | 2 | $43 |
| Pfizer | 3 | $42 |
| Boehringer Ingelheim | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$37,194
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,063
- COREVALVE EVOLUT R$1,229
- SYMPLICITY G3$315
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$275
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$270
- MitraClip$262
- GENERAL - THERAPIES$257
- PASCAL$159
- Indigo System$150
- ONYX FRONTIER$149
- FLASH OSTIAL SYSTEM, FLASH MINI OSTIAL SYSTEM, FLASH OSTIAL SYSTEM OTW$144
- AMPLATZER TALISMAN$138
- Diamondback Peripheral$105
- Diamondback Coronary$105
How this compares
$49,523 in reported general payments places this provider in the 85th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $161,696 |
| JardianceEmpagliflozin | 68 | $86,030 |
| BrilintaTicagrelor | 82 | $61,030 |
| FarxigaDapagliflozin Propanediol | 52 | $58,126 |
| Repatha SureclickEvolocumab | 55 | $55,035 |
| XareltoRivaroxaban | 54 | $45,486 |
| EntrestoSacubitril/Valsartan | 22 | $25,711 |
| Repatha SyringeEvolocumab | 11 | $6,338 |
| Metoprolol Succinate | 245 | $3,039 |
| Atorvastatin Calcium | 233 | $2,469 |
| Ranolazine ErRanolazine | 20 | $2,172 |
| ClopidogrelClopidogrel Bisulfate | 135 | $1,674 |
| Flecainide Acetate | 22 | $1,538 |
| Losartan Potassium | 141 | $1,082 |
| Carvedilol | 98 | $866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $42 | $161,696134 claims |
| Boehringer IngelheimJardiance | $17 | $86,03068 claims |
| Johnson & JohnsonXarelto | $16 | $45,48654 claims |
| NovartisEntresto | $98 | $25,71122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Pueblo
- Derar AlbashairehPueblo$8K
- George GibsonPueblo$7K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.